Home/Pipeline/Internal Antibody Therapeutics Suite

Internal Antibody Therapeutics Suite

Solid Tumors

Pre-clinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

Active

Company

Creasallis

About Creasallis

Creasallis is an early-stage biotech addressing the significant limitation of antibody penetration in solid tumors, where typically only 0.001-7% of a dose reaches the target. Its core asset is the CreaTap platform, a universal modification technology that can be applied to various antibody formats (mAbs, ADCs, bispecifics) and even protein/peptide conjugates to improve tumor penetration. Operating as a platform company, Creasallis plans to both partner its technology for existing drugs and develop its own internal pipeline of enhanced therapeutics.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed